TABLE 2.
Application of 161Tb-DOTATOC, Premedication, and Scan Times
| Characteristic | Patient 1 | Patient 2 |
|---|---|---|
| Premedication to prevent adverse effects | Ondansetron (8 mg), intravenously | Ondansetron (8 mg), intravenously |
| Dexamethasone (8 mg), intravenously | Dexamethasone (8 mg), intravenously | |
| Measures for nephroprotection | Amino acid solution (Lys/Arg) (1,600 mL) intravenously | Electrolyte solution (1,000 mL) intravenously |
| Furosemide (20 mg), intravenously | Furosemide (20 mg), intravenously | |
| Application of 161Tb-DOTATOC | 596 MBq, intravenously (July 2018) | 1,300 MBq, intravenously (November 2018) |
| Planar scans (whole body) | 0.5 h after injection | 0.5 h after injection |
| 3 h after injection | 2.5 h after injection | |
| 24 h after injection | 20 h after injection | |
| 49.5 h after injection | 93 h after injection | |
| 71 h after injection | 113 h after injection | |
| SPECT/CT scan | 22.5 h after injection (thorax) | 19 h after injection (liver and abdomen) |
| 46 h after injection (thorax) | ||
| 46.5 h after injection (abdomen and pelvis) |